Molecular Partners : and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19 - Form 6-K

with 75mg the planned dose for further development



Ensovibep continues to maintain potent in vitro pan-variant activity against all variants of concern identified so... | January 10, 2022

Related Keywords

Hungary ,South Africa ,Zurich ,Züsz ,Switzerland ,United States ,India ,Netherlands ,Shai Biran ,Seth Lewis ,Thomas Schneckenburger ,Patrick Amstutz ,Exchange Commission ,Twitter ,Drug Administration ,Nasdaq ,Novartis ,Molecular Partners ,Novartis Report Positive Topline Data ,Antiviral Therapeutic ,Designed Ankyrin Repeat Protein ,Emergency Use Authorization ,Emergency Room ,Vas Narasimhan ,Designed Ankyrin Repeat Proteins ,Private Securities Litigation Reform Act ,Molecular Partner ,Risk Factors ,Molecular Partner Registration Statement ,Molecular Partners Ag Stock Exchange ,News ,Information ,Press Release ,Ith ,35mg ,The ,Planned ,Nose ,Or ,Urther ,Ensovibep ,Ontinues ,O ,Aintain ,Kpotent ,N ,Itro ,Activity ,Against ,Wall ,Variants ,F ,Concern ,Dentified Moln Ch0256379097 ,